EcoDrugPlus

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSDLEG00000006633
Gene Symbol: HTR2A
3 Cross references
217 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSDLEG00000008642
Gene Symbol: HTR2B
1 Cross references
207 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSDLEG00000021923
Gene Symbol: HTR2C
3 Cross references
226 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSDLEG00000010503
Gene Symbol: HTR3A
3 Cross references
207 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSDLEG00000010470
Gene Symbol: HTR3B
3 Cross references
175 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSDLEG00000003669
Gene Symbol: HTR4
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSDLEG00000014954
Gene Symbol: HTR5A
3 Cross references
216 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSDLEG00000021800
Gene Symbol: HTR7
1 Cross references
221 Possible Orthologues:

60s Ribosomal Protein L23-Like

Ensembl ID : ENSDLEG00000001317
Gene Symbol: LOC111182554
3 Cross references
155 Possible Orthologues:

60s Ribosomal Protein L26-Like

Ensembl ID : ENSDLEG00000021294
Gene Symbol: LOC111178321
3 Cross references
211 Possible Orthologues:

60s Ribosomal Protein L9-Like

Ensembl ID : ENSDLEG00000013048
Gene Symbol: LOC111166056
3 Cross references
155 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSDLEG00000020437
Gene Symbol: ARAF
3 Cross references
192 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).